...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Report Of Exempt Distribution.
3
Apr 16, 2024 03:39PM

"The saga continues"...... Yes, for Resverlogox. 

Zenith on the other hand is doing just fine,..... IMO.

You have a good evening as well fuzzy ..... cheer up. :)

 

Koo

2
Apr 18, 2024 12:30AM
Share
New Message
Please login to post a reply